alexa Editor - Bin Guo | North Dakota State University: NDSU | 8756
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences
Share This Page

Bin Guo

Bin Guo
Bin Guo
Associate Professor
Department of Pharmaceutical Sciences
North Dakota State University
USA
North Dakota State University: NDSU

Biography

Dr. Bin Guo received his B.S. degree from University of Science and Technology of China in 1992, and his PhD from State University of New York at Buffalo in 1999. After a post-doc fellowship at the Burnham Institute in the group of Professor John C. Reed, he joined North Dakota State University in December 2003 as an Assistant Professor of Pharmaceutical Sciences. He was promoted to Associate Professor with tenure in 2010. His research interests focus on the tumor suppressing microRNAs that regulate cancer cell apoptosis and growth. Dr. Guo’s research has been funded by NIH R03, R21, and P20 grants, as well as a grant from Department of Defense. He has served on study sections for Department of Defense and Israel Science Foundation. He is a co-author of two international patents on apoptosis regulatory proteins. In 2009, he was selected in Who’s Who in America.

Research Interest

1. Novel Mechanisms Regulating Cancer Progression. In this project, we study how cancer cells develop apoptosis resistance and metastatic capability as they progress from benign state to malignant cancer. Our research focuses on the epigenetic action and regulation of tumor-suppressing microRNAs. Combining basic research and translational studies, we try to understand the role of miR-205 and miR-31 in human prostate cancer and to develop new therapeutics to overcome drug resistance.
2. Targeting Histone Modifications for Cancer Therapy. In this project, we study how new therapeutic agents induce cell cycle arrest and apoptosis by targeting histone modifications (acetylation and methylation) in cancer cells. Using both in vitro studies and mouse models, we work on developing novel strategies to enhance therapeutic efficacy in the treatment of cancer.

Certificate

Certificate

Global Speakers in the subject

Global Experts in the subject

Top